^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | XMT-1522 (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
Excerpt:
XMT-1522 has been well-tolerated up to the 21.3 mg/m2 dose level with early signs of anti-tumor activity. Neither MTD nor RP2D has been identified. Dose escalation continues in pts with advanced HER2-expressing BC, GC and NSCLC.
DOI:
10.1200/JCO.2018.36.15_suppl.2546
Trial ID:
Source:
Title:
A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
Excerpt:
XMT-1522 had a strong antitumor effect on RN-87 and JIMT-1 xenografts that progressed on T-DM1. We conclude that XMT-1522 was effective in HER2-positive breast cancer and gastric cancer cell lines resistant to T-DM1, and in xenograft models resistant to T-DM1.
DOI:
10.1158/1535-7163.MCT-19-0207
